Pfizer Reports 80% Biosimilars Growth In Q3
Company Expects To Close Upjohn-Mylan Transaction In Q4
Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.
